Skip to main content

New Tool IDs Sexual Struggles in Female Partners of Prostate Cancer Patients

Medically reviewed by Carmen Pope, BPharm. Last updated on May 24, 2024.

By Lori Solomon HealthDay Reporter

FRIDAY, May 24, 2024 -- The Sexual Concerns In Partners of Patients with Prostate cancer tool is a valid measure of sexual health in female partners of patients with prostate cancer, according to a study published online May 17 in European Urology Oncology.

Stacy Loeb, M.D., from NYU Langone Health in New York City, and colleagues described the development and validation of an instrument to measure sexual health in female partners of patients with prostate cancer. The 27-question tool was developed as a result of a literature review, two qualitative studies, and an expert consensus process. The analysis for validation of the tool included questionnaires completed by 200 female partners of patients with prostate cancer.

The researchers reported that exploratory factor analysis eliminated eight items and revealed seven key factors: (1) distress/satisfaction; (2) loss of connection as a couple; (3) active communication; (4) discomfort with communication; (5) frustration with sexual counseling; (6) expansion of sexual repertoire; and (7) nonpenetrative sexual activity. The scale showed strong internal consistency (ordinal alpha, 0.94) and test-retest reliability (0.89).

"Our hope is that clinicians will use our survey to help patients and their partners identify issues in their sex lives that are impacted by this common cancer and to help determine what support services could be useful," Loeb said in a statement. "When thinking about living with prostate cancer, this is really a couples’ disease, and partners’ unmet needs should be part of the conversation."

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted May 2024

Read this next

Higher County-Level Prostate Cancer Screening Tied to Better Outcomes

FRIDAY, June 7, 2024 -- Higher county-level prevalence of prostate-specific antigen (PSA) screening is associated with lower odds of advanced disease, all-cause mortality, and...

First-Line Biparametric MRI Less Cost-Effective Than PSA for Prostate Cancer Screening

MONDAY, June 3, 2024 -- From an economic perspective, first-line prostate-specific antigen (PSA) testing is favored over biparametric magnetic resonance imaging (bpMRI) for...

Active Surveillance Effective Strategy for Favorable-Risk Prostate Cancer

FRIDAY, May 31, 2024 -- Active surveillance is an effective management strategy for men with favorable-risk prostate cancer, with an estimated rate of metastasis of 1.4 percent at...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.